Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Vicagrel in Patients With With Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI): a Multi-center, Randomized, Double-blind, Double-dummy , Parallel-controlled, Phase III Trial

NCT06577519 is registered in ClinicalTrials.gov with Jiangsu vcare pharmaceutical technology co., LTD as lead sponsor.

NCT NCT06577519
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06577519 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Vicagrel in Patients With With Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI): a Multi-center, Randomized, Double-blind, Double-dummy , Parallel-controlled, Phase III Trial
Lead sponsor
Jiangsu vcare pharmaceutical technology co., LTD
Phase
Phase 3
Overall status
Recruiting
Start date
September 6, 2024
Completion date
December 30, 2026
Enrollment
1,000 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute coronary syndrome (acs) undergoing percutaneous coronary intervention (pci)